Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer
A Phase I Trial of Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Anti-prostate-specific Membrane Antigen Monoclonal Antibody in Patients With Metastatic, Castrate-resistant Prostate Cancer
Sponsor: Weill Medical College of Cornell University
A PHASE1 clinical study on Prostate Cancer, this trial is completed. The trial is conducted by Weill Medical College of Cornell University and has accumulated 9 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jun 2021 [monthly]
Completed PHASE1
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Sep 2018 — Oct 2019 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
May 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Weill Medical College of Cornell University
For direct contact, visit the study record on ClinicalTrials.gov .